Movers and SHAKERS
Lineage Cell Therapeutics (LCTX)
Treating Diseases By Transplanting New Cells
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Initiating Coverage of LCTX. Lineage Cell Therapeutics is developing cellular-based therapies for use as standardized, “off-the-shelf” products to restore tissue damaged by disease processes. The company has developed a proprietary technology for growing early cells into mature cell lines of differentiated, functional tissue components. These cells are then implanted to restore areas of dead or damaged cells.
Lead Product is In Dry AMD. The company’s technology directs cells to differentiate along specific cell lines, guiding them to mature into functional tissue components. Its lead product, OpRegen, is in development for dry age-related macular degeneration, or dry AMD. Interim results from a Phase 1/2a trial RPE were updated in July 2021, with the next clinical trial planned in late 2021-early 2022 ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.